Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2
GLP-1RAs overcome the limitations of endogenous GLP-1 and traditional hypoglycemic drugs, providing a new strategy for the comprehensive treatment of T2DM featuring "hypoglycemia-organ protection-weight loss". The mechanisms and pathway networks analyzed in this study lay a foundation for the precise intervention of T2DM and rational clinical drug use.
Authors
- Jing Cynthia Wu (ORCID: https://orcid.org/0000-0003-4239-1233)
- Jingxin Mao (ORCID: https://orcid.org/0000-0002-2813-1702)
- Qian Hu (ORCID: https://orcid.org/0000-0003-0587-6346)
- Qian Shao (ORCID: https://orcid.org/0000-0001-9921-9667)
- Juan Xiong
Institutions
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical and Pharmaceutical College (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Molecular Biosciences
- Published
- 2026-01-07
- DOI
- https://doi.org/10.3389/fmolb.2025.1729904
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chongqing Municipal Education Commission
- Centre Scientifique et Technique du Bâtiment